Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

References

• Chiricozzi A, Veraldi S, Fabbrocini G, et al. The Hidradenitis Suppurativa (HS) “multidisciplinary unit”: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol. 2018;28(2):274–275. doi:10.1684/ejd.2018.3254
   PubMed Web of Science ®Google Scholar
• Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? Skin Appendage Disord. 2022;8(3):265–268. doi:10.1159/000521712
   PubMed Web of Science ®Google Scholar
• Jemec GB. Clinical practice Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–164. doi:10.1056/NEJMcp1014163
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa ?-15 years after. Exp Dermatol. 2020;29(12):1154–1170. doi:10.1111/exd.14214
   PubMed Web of Science ®Google Scholar
• de Oliveira ASLE, Bloise G, Moltrasio C, et al. Transcriptome meta-analysis confirms the hidradenitis suppurativa pathogenic triad: upregulated inflammation, altered epithelial organization, and dysregulated metabolic signaling. Biomolecules. 2022;12(10):1371. doi:10.3390/biom12101371
   PubMed Web of Science ®Google Scholar
• Benzecry V, Grancini A, Guanziroli E, et al. Hidradenitis suppurativa/acne inversa: a prospective bacteriological study and review of the literature. G Ital Dermatol Venereol. 2020;155(4):459–463. doi:10.23736/S0392-0488.18.05875-3
   PubMed Web of Science ®Google Scholar
• Kaleta KP, Nikolakis G, Hossini AM, et al. Metabolic disorders/obesity is a primary risk factor in hidradenitis suppurativa: an immunohistochemical real-world approach. Dermatology. 2022;238(2):251–259. doi:10.1159/000517017
   PubMed Web of Science ®Google Scholar
• Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092–1101. doi:10.1016/j.jaad.2021.01.059
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Cacciapuoti S, et al. A dermatological questionnaire for general practitioners with a focus on hidradenitis suppurativa. Open Access Maced J Med Sci. 2018;6(10):1902–1905. doi:10.3889/oamjms.2018.358
   PubMedGoogle Scholar
• Veraldi S, Guanziroli E, Benzecry V, Nazzaro G. Multidisciplinary approach for hidradenitis suppurativa patients. G Ital Dermatol Venereol. 2018;153(3 Suppl 2):18–19. doi:10.23736/S0392-0488.17.05779-0
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(Suppl 1):8–17. doi:10.1111/exd.14338
   PubMedGoogle Scholar
• Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol. 2020;82(5):1061–1082. doi:10.1016/j.jaad.2019.08.089
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422. doi:10.1056/NEJMoa1504370
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181(5):967–975. doi:10.1111/bjd.17919
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Battista T, Fabbrocini G, Ruggiero A. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’. Clin Exp Dermatol. 2022;47:2026–2028. doi:10.1111/ced.15306
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• AbbVie. Humira; 2017. Available from: http://www.rxabbvie.com/pdf/humira.pdf. Accessed December 31, 2018.
   Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–855. doi:10.7326/0003-4819-157-12-201212180-00004
   PubMed Web of Science ®Google Scholar
• Kimball AB, Sundaram M, Shields AL, et al. Adalimumab alleviates skin pain in patients with moderate to severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018;79:1141–1143. doi:10.1016/j.jaad.2018.05.015
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term Adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69. e2. doi:10.1016/j.jaad.2018.05.040
   PubMed Web of Science ®Google Scholar
• Ryan C, Sobell JM, Leonardi CL, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19(3):437–447. doi:10.1007/s40257-017-0341-6
   PubMed Web of Science ®Google Scholar
• Marzano AV, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with Adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140. doi:10.1111/bjd.18983
   PubMed Web of Science ®Google Scholar
• Bettoli V, Manfredini M, Calamo G, et al. Long-term Adalimumab treatment of hidradenitis suppurativa: results and practical insights from a real-life experience. Dermatol Ther. 2018;31(6):e12737. doi:10.1111/dth.12737
   PubMed Web of Science ®Google Scholar
• Martorell A, Caballero A, González Lama Y, et al. Management of patients with hidradenitis suppurativa. Manejo del paciente con hidradenitis supurativa. Actas Dermosifiliogr. 2016;107(Suppl 2):32–42. doi:10.1016/S0001-7310(17)30007-8
   PubMedGoogle Scholar
• Chiricozzi A, Giovanardi G, Garcovich S, et al. Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: a real-life monocentric experience. Acta Derm Venereol. 2020;100(13):adv00172. doi:10.2340/00015555-3520
   PubMedGoogle Scholar
• Hafner A, Ghislain PD, Kovács R, et al. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with Adalimumab: real-world results from the HARMONY Study. J Eur Acad Dermatol Venereol. 2021;35(11):2277–2284. doi:10.1111/jdv.17551
   PubMed Web of Science ®Google Scholar
• Gulliver W, Alavi A, Wiseman MC, et al. Real-world moderate-to-severe hidradenitis suppurativa: decrease in disease burden with Adalimumab. J Cutan Med Surg. 2022;26(4):361–370. doi:10.1177/12034754221088584
   PubMed Web of Science ®Google Scholar
• Muralidharan V, Pathmarajah P, Peterknecht E, et al. Real-life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: a multicenter cross-sectional analysis and consideration of a multisystem monitoring approach to follow up. Dermatol Ther. 2021;34(1):e14643. doi:10.1111/dth.14643
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A. Efficacy of Adalimumab in moderate to severe hidradenitis suppurativa: real life data. Dermatol Reports. 2018;10(2):7859. doi:10.4081/dr.2018.7859
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Rozzo G, Burzi L, et al. Switching from Adalimumab originator to biosimilars in hidradenitis suppurativa: what’s beyond cost-effectiveness? Dermatol Ther. 2022;35:e15803. doi:10.1111/dth.15803
   PubMed Web of Science ®Google Scholar
• Hayashi N, Hayama K, Takahashi K, et al. Real-world safety and effectiveness of Adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. J Dermatol. 2022;49(4):411–421. doi:10.1111/1346-8138.16297
   PubMed Web of Science ®Google Scholar
• Neves JM, Cunha N, Lencastre A, Cabete J. Treating hidradenitis suppurativa patients with Adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal. An Bras Dermatol. 2022;97(6):816–819. doi:10.1016/j.abd.2021.12.004
   PubMed Web of Science ®Google Scholar
• Caposiena Caro RD, Chiricozzi A, Sechi A, et al. Flares as dynamic predictive factor of response to Adalimumab in hidradenitis suppurativa: real-life data. Ital J Dermatol Venerol. 2022;157(3):240–246. doi:10.23736/S2784-8671.21.07049-3
   PubMedGoogle Scholar
• Nazzaro G, Calzari P, Passoni E, et al. Vascularization and fibrosis are important ultrasonographic tools for assessing response to Adalimumab in hidradenitis suppurativa: prospective study of 32 patients. Dermatol Ther. 2021;34(1):e14706. doi:10.1111/dth.14706
   PubMed Web of Science ®Google Scholar
• Bahillo Monné C, Honorato Guerra S, Schoendorff Ortega C, Gargallo Quintero AB. Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature. Dermatology. 2014;229(4):279–287. doi:10.1159/000365076
   PubMed Web of Science ®Google Scholar
• Gorovoy I, Berghoff A, Ferris L. Successful treatment of recalcitrant hidradenitis suppurativa with Adalimumab. Case Rep Dermatol. 2009;1(1):71–77. doi:10.1159/000251217
   PubMedGoogle Scholar
• Harde V, Mrowietz U. Treatment of severe recalcitrant hidradenitis suppurativa with Adalimumab. J Dtsch Dermatol Ges. 2009;7(2):139–141. doi:10.1111/j.1610-0387.2008.06918.x
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Mau N. Hidradenitis suppurativa managed with Adalimumab. J Drugs Dermatol. 2009;8(2):181–183.
   PubMed Web of Science ®Google Scholar
• Bosnić D, Žarković B, Barešić M, Zarkovic M, Anic B. Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of Adalimumab. Reumatologia. 2016;54(6):321–325. doi:10.5114/reum.2016.64910
   PubMedGoogle Scholar
• Diamantova D, Lomickova I, Cetkovska P. Adalimumab treatment for hidradenitis suppurativa associated with Crohn’s disease. Acta Dermatovenerol Croat. 2014;22(4):291–293.
   PubMed Web of Science ®Google Scholar
• Murphy B, Morrison G, Podmore P. Successful use of Adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis. Int J Colorectal Dis. 2015;30(8):1139–1140. doi:10.1007/s00384-014-2110-9
   PubMed Web of Science ®Google Scholar
• Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with Adalimumab. Dermatol Online J. 2010;16(8):15. doi:10.5070/D34PH5R1M2
   PubMedGoogle Scholar
• Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis supprativa with Adalimumab. J Am Acad Dermatol. 2006;55(1):163–164. doi:10.1016/j.jaad.2006.01.024
   PubMed Web of Science ®Google Scholar
• De Wet J, Jordaan HF, Kannenberg SM, Tod B, Glanzmann B, Visser WI. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with Adalimumab. Dermatol Online J. 2017;23:12. doi:10.5070/D32312037669
   Google Scholar
• Saraceno R, Babino G, Chiricozzi A, Zangrilli A, Chimenti S. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol. 2015;72(1):e42–44. doi:10.1016/j.jaad.2014.10.002
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. doi:10.1001/jamadermatol.2022.2909
   PubMed Web of Science ®Google Scholar
• Yu Q, Ge X, Jing M, et al. A systematic review with meta-analysis of comparative efficacy and safety of risankizumab and ustekinumab for psoriasis treatment. J Immunol Res. 2022;2022:2802892. doi:10.1155/2022/2802892
   PubMed Web of Science ®Google Scholar
• Ye L, Wu Z, Li C, Zhao X, Wan M, Wang L. Off-label uses of ustekinumab. Dermatol Ther. 2022;35:e15910. doi:10.1111/dth.15910
   PubMed Web of Science ®Google Scholar
• Hollywood A, Murray G, Fleming S, Kirby B, Hughes R. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. J Drugs Dermatol. 2022;21(3):319–320. doi:10.36849/JDD.6298
   PubMedGoogle Scholar
• Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, Vega-Gutiérrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat. 2022;33(1):348–353. doi:10.1080/09546634.2020.1755008
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP. Successful long-term triple disease control by ustekinumab in a patient with Behcet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626–627. doi:10.1136/annrheumdis-2012-202392
   PubMed Web of Science ®Google Scholar
• Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839–846. doi:10.1111/bjd.14338
   PubMed Web of Science ®Google Scholar
• Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911–914. doi:10.1111/j.1468-3083.2011.04123.x
   PubMed Web of Science ®Google Scholar
• Santos-Pérez MI, García-Rodicio S, Del Olmo-Revuelto MA, Pozo-Román T. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr. 2014;105(7):720–722. doi:10.1016/j.ad.2013.09.011
   PubMedGoogle Scholar
• Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92(3):320–321. doi:10.2340/00015555-1229
   PubMed Web of Science ®Google Scholar
• Romaní J, Vilarrasa E, Martorell A, Fuertes I, Ciudad C, Molina-Leyva A. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatology. 2020;236(1):21–24. doi:10.1159/000501075
   PubMed Web of Science ®Google Scholar
• Scholl L, Hessam S, Garcovich S, Bechara FG. High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. Eur J Dermatol. 2019;29(6):659–661. doi:10.1684/ejd.2019.3663
   PubMed Web of Science ®Google Scholar
• Jiang SW, Kwock JT, Liu B, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022;187(3):417–419. doi:10.1111/bjd.21066
   PubMed Web of Science ®Google Scholar
• Takeda K, Kikuchi K, Kanazawa Y, Yamasaki K, Aiba S. Ustekinumab treatment for hidradenitis suppurativa. J Dermatol. 2019;46(12):1215–1218. doi:10.1111/1346-8138.15122
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar
• Ruggiero A, Marasca C, Villani A, Fabbrocini G, Martora F. Tacrolimus ointment may improve the effectiveness of Adalimumab in patients with hidradenitis suppurativa: a novel promising treatment. Clin Exp Dermatol. 2022;47(10):1871–1872. doi:10.1111/ced.15299
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Martora F, Picone V, Morelli P, Patruno C. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases. Cells. 2021;10(12):3559. doi:10.3390/cells10123559
   PubMed Web of Science ®Google Scholar
• Secukinumab. Drugs and Lactation Database (Lactmed). Bethesda (MD): National Library of Medicine (US); 2022.
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Wu KK, Dao H. Off-label dermatologic uses of IL-17 inhibitors. J Dermatolog Treat. 2022;33(1):41–47. doi:10.1080/09546634.2020.1737638
   PubMed Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181:609–611. doi:10.1111/bjd.17822
   PubMed Web of Science ®Google Scholar
• Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35. doi:10.1111/jdv.17178
   Web of Science ®Google Scholar
• Marasca C, Megna M, Balato A, Balato N, Napolitano M, Fabbrocini G. Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep. 2019;5(2):184–187. doi:10.1016/j.jdcr.2018.12.002
   PubMedGoogle Scholar
• Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182–185. doi:10.1111/bjd.15769
   PubMed Web of Science ®Google Scholar
• Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151–152. doi:10.2340/00015555-2794
   PubMed Web of Science ®Google Scholar
• Jørgensen AR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;2018:8685136. doi:10.1155/2018/8685136
   PubMedGoogle Scholar
• Ixekizumab. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2017.
   Google Scholar
• Marasca C, Fornaro L, Martora F, Picone V, Fabbrocini G, Megna M. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102. doi:10.1111/dth.15102
   PubMed Web of Science ®Google Scholar
• Martora F, Battista T, Fornaro L, et al. Generalized versus localized vitiligo after ixekizumab: may previous treatment affect the clinical presentation? Dermatol Ther. 2022;35:e15874. doi:10.1111/dth.15874
   PubMed Web of Science ®Google Scholar
• Cotter C, Tobin AM, O’Connor R, et al. Severe refractory hidradenitis suppurativa: treatment with ixekizumab, two case reports. Bristol Cup. 2018;179:24–73.
   Google Scholar
• Esme P, Botsali A, Akoglu G, Caliskan E. An anti-interleukin-17A monoclonal antibody, ixekizumab, in the treatment of resistant hidradenitis suppurativa: a case series. Skin Appendage Disord. 2022;8(4):342–345. doi:10.1159/000521860
   PubMedGoogle Scholar
• Megna M, Ruggiero A, Di Guida A, Patrì A, Fabbrocini G, Marasca C. Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther. 2020;33(4):e13756. doi:10.1111/dth.13756
   PubMed Web of Science ®Google Scholar
• Navrazhina K, Frew JW, Grand D, et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol. 2022;187(2):223–233. doi:10.1111/bjd.21060
   PubMedGoogle Scholar
• Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. Dermatol Ther. 2020;33(3):e13456. doi:10.1111/dth.13456
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. doi:10.1080/17512433.2020.1767590
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22:1–18.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol. 2022;47:2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar
• Wu JJ, Liu J, Thatiparthi A, et al. The risk of COVID-19 in patients with psoriasis: a retrospective cohort study. J Am Acad Dermatol. 2022;S0190–9622(22):2417
   Google Scholar
• He M, Ferris LK, Gabriel N, et al. COVID-19 and adherence to biologic therapies for psoriasis: an analysis of nationwide pharmacy claims data. J Manag Care Spec Pharm. 2022;28(11):1213–1218. doi:10.18553/jmcp.2022.28.11.1213
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, et al. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022;21:5339–5340. doi:10.1111/jocd.15331
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, et al. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15414
   Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, et al. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750–e751. doi:10.1111/jdv.18302
   PubMed Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. ”Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G. Video, and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863–1864. doi:10.1111/ced.15286
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22:1–3.
   PubMed Web of Science ®Google Scholar
• Mintoff D, Benhadou F. Guselkumab does not appear to influence the IgG antibody response to SARS-CoV-2. Dermatol Ther. 2022;35(2):e15246. doi:10.1111/dth.15246
   PubMed Web of Science ®Google Scholar
• Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous reactions following COVID-19 vaccination: a review of the current literature. Clin Cosmet Investig Dermatol. 2022;15:2369–2382. doi:10.2147/CCID.S388245
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, et al. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Picone V, Fabbrocini G, Martora L, Martora F. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
   Web of Science ®Google Scholar
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Ruggiero A, et al. Towards Personalized Medicine in Psoriasis: current Progress. Psoriasi. 2022;12:231–250. doi:10.2147/PTT.S328460
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47:2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Marasca C, Marasca D, Megna M, Annunziata MC, Fabbrocini G. Ultrasound: an indispensable tool to evaluate the outcome of surgical approaches in patients affected by hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34(8):e413–e414. doi:10.1111/jdv.16361
   PubMed Web of Science ®Google Scholar
• Krajewski PK, Jfri A, Ochando-Ibernón G, Martorell A. Ultrasonographic railway sign in tunnels as a new independent risk factor of Adalimumab failure in hidradenitis suppurativa. J Am Acad Dermatol. 2022. doi:10.1016/j.jaad.2022.08.064
   PubMed Web of Science ®Google Scholar
• Nazzaro G, Passoni E, Calzari P, Marzano AV. Ultrasonographic assessment of fibrosis in hidradenitis suppurativa fistulae helps in addressing treatment. Skin Res Technol. 2020;26(3):445–446. doi:10.1111/srt.12805
   PubMed Web of Science ®Google Scholar
• Nazzaro G, Passoni E, Calzari P, et al. Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions. Skin Res Technol. 2019;25(6):830–834. doi:10.1111/srt.12729
   PubMed Web of Science ®Google Scholar